3D Movie Viewing vs Occlusion for Treating Amblyopia in Children (VISTA3D)
Efficacy of 3D Movie Viewing Versus Occlusion on Stereopsis and Visual Function in Children With Amblyopia: A Randomized Controlled Trial
Amblyopia is a common childhood visual disorder that affects vision in one eye and can also impair depth perception (stereopsis). Standard treatment typically involves occlusion therapy (patching the stronger eye), which improves visual acuity but often does not fully restore binocular vision.
This study aims to evaluate whether watching 3D movies, combined with occlusion therapy, improves visual outcomes more than occlusion therapy alone in children with amblyopia. The immersive nature of 3D content may stimulate binocular vision and enhance treatment effectiveness.
In this randomized controlled trial, children aged 4 to 14 years with amblyopia will be assigned to one of two groups: one group will receive standard occlusion therapy, while the other will receive occlusion combined with weekly 3D movie sessions. After an initial phase, all participants will have access to 3D viewing sessions.
The study will assess improvements in depth perception, visual acuity, and eye alignment over time. The goal is to determine whether this combined approach provides additional benefits and could be used as a complementary therapy for amblyopia.
調査の概要
詳細な説明
Amblyopia is the leading cause of monocular visual impairment in children, with a prevalence of approximately 2-3%. It is commonly associated with strabismus and/or anisometropia and is characterized by reduced visual acuity and deficits in binocular vision, particularly stereopsis. While conventional treatments such as refractive correction and occlusion therapy are effective in improving visual acuity, many patients retain residual deficits in stereopsis and binocular function.
Recent advances in amblyopia treatment have focused on binocular approaches, including perceptual learning, dichoptic training, and virtual reality-based interventions. These methods aim to stimulate binocular interaction and reduce suppression of the amblyopic eye. Among these approaches, 3D movie viewing represents a naturalistic and engaging stimulus that introduces large binocular disparities and may promote binocular integration in a child-friendly environment.
Preliminary evidence from a pilot study conducted by our group demonstrated that a single 3D movie session can produce significant and sustained improvements in stereopsis and visual acuity in children with a history of amblyopia. However, this study lacked a control group and involved only a single exposure session.
The present study is a prospective, randomized, controlled, single-center clinical trial designed to evaluate the efficacy of repeated 3D movie viewing sessions combined with occlusion therapy compared to occlusion therapy alone. Participants will be randomly assigned to either an experimental group (3D viewing plus occlusion) or a control group (occlusion alone). The intervention will consist of 3 to 6 weekly sessions of 3D movie viewing, each lasting approximately 90-120 minutes.
The study includes two phases: an initial comparative phase in which outcomes between groups are assessed after three sessions, and a second phase in which all participants are exposed to additional 3D sessions to evaluate cumulative effects. Assessments will be conducted at baseline (T0), after the first phase (T1), and after completion of all sessions (T2).
Primary outcome measures include stereopsis (measured in log arcseconds), visual acuity (logMAR), and ocular deviation (prism diopters). Secondary outcomes include sensory and motor characteristics (fusion, suppression, retinal correspondence), treatment adherence, and patient-reported satisfaction and quality of life.
Outcome assessors will be masked to group allocation to reduce bias. The study also aims to explore factors influencing treatment response, including age and type of amblyopia.
This trial seeks to determine whether 3D movie viewing can serve as an effective, engaging, and non-invasive adjunct to conventional amblyopia treatment, with potential implications for improving both visual function and patient adherence.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Laura Asensio Jurado, PhD
- 電話番号：0034636760450
- メール：asensiojlaura@upc.edu
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Children aged 4 to 14 years Diagnosis of unilateral amblyopia (anisometropic, strabismic, or mixed) Interocular visual acuity difference ≥ 0.2 logMAR (equivalent to ≥ 2 Snellen lines) Ability to understand and follow age-appropriate instructions Written informed consent from parents or legal guardians Child assent obtained when applicable
Exclusion Criteria:
Previous treatment for amblyopia Ocular surgery within the last 6 months Strabismus with deviation greater than 10 prism diopters Presence of other ocular pathologies affecting vision (e.g., cataract, nystagmus, ptosis, corneal opacity, retinal disease, optic neuropathy) Neurological or cognitive impairment preventing compliance with study procedures Prior intensive exposure to 3D movies or virtual reality/3D video games that could act as a confounding factor Refusal of the child or family to participate
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：3D Movie Viewing + Occlusion
Participants will receive standard occlusion therapy combined with 3D movie viewing sessions.
The intervention consists of 3 weekly sessions (Phase 1), followed by 3 additional sessions (Phase 2), each lasting 90-120 minutes, in a controlled environment.
|
Participants will watch 3D movies using active shutter glasses in a controlled environment.
Sessions will be conducted once weekly, each lasting approximately 90-120 minutes, over a total of 3 to 6 sessions.
This intervention aims to stimulate binocular vision through exposure to large binocular disparities in an immersive and engaging setting.
Standard occlusion therapy of the non-amblyopic eye prescribed according to clinical guidelines and amblyopia severity.
Treatment is performed at home for a specified number of hours per day, depending on clinical indication, with the goal of improving visual acuity in the amblyopic eye.
|
|
アクティブコンパレータ：Occlusion Therapy
Participants will receive standard occlusion therapy according to clinical guidelines based on amblyopia severity during Phase 1.
In Phase 2, participants will also undergo 3D movie viewing sessions.
|
Standard occlusion therapy of the non-amblyopic eye prescribed according to clinical guidelines and amblyopia severity.
Treatment is performed at home for a specified number of hours per day, depending on clinical indication, with the goal of improving visual acuity in the amblyopic eye.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Stereopsis (RANDOT)
時間枠：Baseline (T0) to 3 weeks (T1)
|
Stereopsis will be assessed using a validated stereopsis test (Random Dot 2 Test).
Results will be expressed in log arcseconds.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Visual Acuity
時間枠：Baseline (T0) to 3 weeks (T1)
|
Visual acuity will be measured using standardized ETDRS charts and expressed in logMAR.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Ocular Deviation
時間枠：Baseline (T0) to 3 weeks (T1)
|
Ocular deviation will be assessed using cover test and prism bars at distance (6 m) and near (40 cm), expressed in prism diopters (PD), distinguishing esotropia and exotropia.
|
Baseline (T0) to 3 weeks (T1)
|
|
Change in Stereopsis ( StereoTAB)
時間枠：Baseline (T0) to 3 weeks (T1)
|
Stereopsis will be assessed using a validated stereopsis test (StereoTAB Test).
Results will be expressed in log arcseconds.
|
Baseline (T0) to 3 weeks (T1)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Binocular Function (Fusion and Suppression)
時間枠：Baseline (T0) to 3 weeks (T1)
|
Binocular sensory status will be evaluated using the Worth 4 Dot test to assess fusion and suppression.
|
Baseline (T0) to 3 weeks (T1)
|
|
Retinal Correspondence
時間枠：Baseline (T0) to 3 weeks (T1)
|
Retinal correspondence will be assessed using the Bagolini striated lenses test.
|
Baseline (T0) to 3 weeks (T1)
|
|
Treatment Adherence
時間枠：Up to 6 weeks
|
Adherence will be measured as the number of completed sessions and reported hours of occlusion therapy.
|
Up to 6 weeks
|
|
Adverse Events and Visual Symptoms
時間枠：Up to 6 weeks
|
Occurrence of symptoms such as headache, visual fatigue, or blurred vision will be recorded using a structured questionnaire.
|
Up to 6 weeks
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Bridgeman B. Restoring adult stereopsis: a vision researcher's personal experience. Optom Vis Sci. Jun 2014;91(6):e135-9. doi:https://doi.org/10.1097/opx.0000000000000272
- Asensio-Jurado L, Argilés M, Quevedo-Junyent L, Mestre C, Levi DM. Can viewing a 3D movie improve visual function in children with a history of amblyopia and neurotypical children?: A pilot study. PLoS One. 2024;19(6):e0305401. doi:https://doi.org/10.1371/journal.pone.0305401
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PDE2LAJ.VISTA3D
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。